Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Rozsa, Csilla; Grammond, Pierre; Alroughani, Raed; Duquette, Pierre; Girard, Marc; Pucci, Eugenio; Lechner-Scott, Jeannette; Slee, Mark; Fernandez-Bolanos, Ricardo; Grand'Maison, Francois; Hupperts, Raymond; Verheul, Freek; Hodgkinson, Suzanne; Oreja-Guevara, Celia; Spitaleri, Daniele; Barnett, Michael; Terzi, Murat; Bergamaschi, Roberto; McCombe, Pamela; Sanchez-Menoyo, Jose; Simo, Magdolna; Csepany, Tunde; Rum, Gabor; BOZ, CAVİT; Havrdova, Eva; Butzkueven, Helmut

doi:10.1002/ana.24339

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...More

ANNALS OF NEUROLOGY, vol.77, no.3, pp.425-435, 2015 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 77 Issue: 3
Publication Date: 2015
Doi Number: 10.1002/ana.24339
Journal Name: ANNALS OF NEUROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.425-435
Open Archive Collection: AVESIS Open Access Collection
Ondokuz Mayıs University Affiliated: Yes

Abstract

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.